High density lipoprotein complete list of trials: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) m (Rim Halaby moved page High density lipoprotein landmark trials to High density lipoprotein complete list of trials) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{High density lipoprotein}} | {{High density lipoprotein}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{Hilda}} | ||
==Reconstituted HDL Infusion== | ==Reconstituted HDL Infusion== | ||
{| class="wikitable sortable" style="font-size:90%" | {| class="wikitable sortable" style="font-size:90%" | ||
Revision as of 14:57, 19 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein complete list of trials On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein complete list of trials |
|
High density lipoprotein complete list of trials in the news |
|
Risk calculators and risk factors for High density lipoprotein complete list of trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hilda Mahmoudi M.D., M.P.H.[2]
Reconstituted HDL Infusion
| Name of the Trial | Official Title | Status | ClinicalTrials.gov Identifier | Drug name | Trial phase |
|---|---|---|---|---|---|
| CHI-SQUARE Study | CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome | Ongoing | |||
| CSL-112 Trial - Phase 1 A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers | An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers | Completed | NCT01281774 | CSL112 (reconstituted HDL) | 1 |
| Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers | An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers | Completed | NCT01129661 | CSL112 (reconstituted HDL) | 1 |
| CSL-112 Trial - Phase 2 | A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112in Patients With Stable Atherothrombotic Disease | Completed | |||
| ERASE Trial | Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound | Completed | |||
| Infusion of Apo A-1 Milano | A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy | Completed |
CETP Inhibitors
| Name of the Trial | Official Title | Status | ClinicalTrials.gov Identifier | Drug name | Trial phase |
|---|---|---|---|---|---|
| ACCELERATE Trial | Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes | Ongoing | NCT01687998 | Evacetrapib | 3 |
| A Study of LY2484595 in Patients With High LDL-C or Low HDL-C | A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C | Completed | Dalcetrapib | ||
| A Study of LY2484595 in Japanese Subjects | A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects | Completed | Dalcetrapib | ||
| A Study of LY2484595 on Pharmacokinetics in Healthy Subjects | A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects | Completed | Dalcetrapib | ||
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome dal-OUTCOMES Trial | A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome | Completed | NCT00658515 | Dalcetrapib | 3 |
| A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers | A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers | Completed | NCT01363999 | Dalcetrapib | |
| A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease | A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD) | Completed | NCT01516541 | Dalcetrapib | |
| A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease | A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography | Completed | NCT01059682 | Dalcetrapib | |
| A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE) | A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE) | Completed | NCT01323153 | Dalcetrapib | |
| A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers | An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects | Completed | NCT01476267 | Dalcetrapib | |
| A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome | A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent | Completed | NCT00353522 | Dalcetrapib | |
| A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patient | A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents | Completed | NCT00655538 | Dalcetrapib | |
| A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381 | A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381 | Completed | NCT00400439 | Dalcetrapib | |
| A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease | A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors | Completed | NCT00655473 | Dalcetrapib | |
| DEFINE TrialStudy to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019 AM6; EXT1 [AM2]) (DEFINE) | A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease | Ongoing | NCT00685776 | Anacetrapib | 3 |
| A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1) | A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C | Ongoing | NCT01717300 | Anacetrapib | 3 |
| A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1) | A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia | Ongoing | NCT01760460 | Anacetrapib | 3 |
| Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039) | A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency | Completed | NCT01114490 | Anacetrapib | 1 |
| A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050) | A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia | Ongoing | NCT01824238 | Anacetrapib | 3 |
| Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038) | A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function | Completed | NCT01122667 | Anacetrapib | 1 |
| REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification | REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease | Ongoing | NCT01252953 | Anacetrapib | 3 |
| Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042 AM2) | A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH) | Ongoing | NCT01841684 | Anacetrapib | 3 |
| A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4) | A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C | Ongoing | NCT01860729 | Anacetrapib | 3 |
| A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022 AM4) | A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C | Ongoing | NCT01860729 | Anacetrapib | 3 |
| Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020 AM1) (REALIZE) | A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia | Ongoing | NCT01524289 | Anacetrapib | 3 |
| A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)(COMPLETED) | A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia | Completed | NCT00977288 | Anacetrapib | 2 |
| The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3) | A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients | Completed | NCT00990808 | Anacetrapib | 1 |
| MK0859 Dose-Ranging Study (0859-003 | MK0859 Dose-Ranging Study | Terminated | NCT00325455 | Anacetrapib | 2 |
| A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia | Completed | NCT00565292 | Anacetrapib | 1 | |
| ILLUSTRATE Trial | |||||
| REVEAL Trial |
Niacin
| AIM-HIGH Trial |
| ARBITER 2 Trial |
| ARBITER 3 Trial |
| ARBITER 6-HALTS Trial |
| CLAS Trial |
| HATS Trial |
| Oxford Niaspan Study |
Fibrate
| VA-HIT Trial |
| BECAIT Trial |
| BIP Trial |
Statin
| ASTEROID Trial |
| SATURN Trial |
| 4S Trial |
| CORONA Trial |
Multiple Lipid Lowering Drugs
| HARP Study |
| AFREGS Trial |
Other trials
| Name of the Trial | Official Name | Status | ClinicalTrials.gov Identifier | |
| Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia | A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia | completed | NCT00688896 | |
| Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia | A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia | Completed | NCT00686010 | |
| Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels | A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels | Completed | NCT00689442 | |
| Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels | A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels | completed | NCT00688558 |
|